Clinical Trials

Clinical Trials

clinical trialClinical trials are research studies in which people help doctors find ways to improve health and cancer care. Each study tries to answer scientific questions and to find better ways to prevent, diagnose, or treat cancer.

A clinical trial is one of the final stages of a long and careful cancer research process. Trials involving patients are only approved for conduct after many other studies are completed in the laboratory setting that demonstrate effectiveness and safety in other models. Studies are done with cancer patients to find out whether promising approaches to cancer prevention, diagnosis, and treatment are safe and effective.

There are several different types of cancer clinical trials:

  • Treatment trials test new treatments to see if they are more effective and/or cause fewer side effects than current treatments available for specific types of cancers. New treatments that are included in cancer clinical trials include but are not limited to a new cancer drug, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy.
  • Prevention trials test new approaches, such as medicines, vitamins, minerals, or other supplements that doctors believe may lower the risk of a certain type of cancer. These trials look for the best way to prevent cancer in people who have never had cancer or to prevent cancer from coming back or a new cancer occurring in people who have already had cancer.
  • Screening trials test the best way to find cancer, especially in its early stages.
  • Quality of Life trials - also called Supportive Care trials - explore ways to improve comfort and quality of life for cancer patients. These trials may evaluate more effective ways to manage cancer pain, decrease fatigue or increase overall well-being during cancer and its treatment.

Below is a list of clinical trials currently being recruited for. For more information on clinical trials or to participate in one of our open trials, please contact our Research Coordinator via email or via phone at 856-218-5790.

Name Summary Objectives
A011106 - Alternate approaches for clinical stage II or III Estrogen Receptor positive breast cancer Neoadjuvant Treatment (ALTERNATE) in postmenopausal women: A Phase III Study

This study is a clinical trial looking at options for treating the cancer before you have surgery.

One purpose of this study is to determine whether

Fulvestrant (faslodex), or fulvestrant plus arimidex, is superior than arimidex alone in shrinking the tumor before surgery. An important part of this trial is to examine whether

the breast cancer is responding adequately to the endocrine (drug) therapy drug by measuring a growth marker in the cancer called Ki67.

S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Patients are given everolimus or placebo daily for one year.

The primary objective of this study is to compare whether the addition of one year of

everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive

disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive

and HER2-negative breast cancer.

S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer

RxPONDER's goal is to help doctors and their patients with breast cancer make better treatment decisions by using a genomic test known as the Oncotype DX® Assay. Patients with hormone receptor-positive breast cancer that has spread to their lymph nodes usually get both chemotherapy and hormonal therapy after surgery. But for some of these patients with low to intermediate "recurrence scores" on the Oncotype DX test, chemotherapy may offer little or no benefit. Hormonal therapy alone may be enough.


For patients with node-positive, hormone-receptor positive, HER2 negative breast cancer who also have low to intermediate Oncotype DX recurrence scores, what are the benefits -- if any -- from adding chemotherapy to hormonal therapy after surgery? 












NRG-BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

For Patients with Triple Negative breast cancer

This trial adds another chemotherapy agent to the standard treatment to see if this will improve disease free survival

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial


Screening Trial for Lung Cancer patients

The purpose of the trial is to test the tumor cells of patients with a certain type of lung cancer to see if they have any genetic changes that would respond to targeted drug therapy.

EAY131 Molecular Analysis for Therapy Choice (MATCH)

Screening study for patient with Refractory solid tumors or lymphomas

The purpose of the study is to determine if targeted therapy will work better than standard chemotherapy in patients whose tumors are refractory to treatment and no other standard treatment exsists.

C80702 A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

A trial of standard chemotherapy  vs chemotherapy plus celebrex

This trial asks the question Does less chemotherapy work as well (previous studies show it does) and does the addition of Celebrex improve outcomes

Clinical Trial Links

Breast Cancer Clinical Trials

Clinical Trial Search Tool

Key Patient Contacts

Louise M. Baca RN MSN - Cancer Center Administrator

Oncology Nurse Navigator
Appointment scheduling and treatment navigation.

Abigale Hassel, MSW, LCSW, OSW-C - Social Worker
Patient support and information.

Cancer Center Accreditations

Commission on Cancer, ACR, NAPBC, Screening Center of Excellence

Upcoming Classes

Well-Being Yoga - Tuesday Afternoon - 12/01/2015
Yoga, which increases flexibility, range of motion and strength, may bring additional benefits both during and after cancer treatments. When tension is released, energy flows more easily in the body, allowing participants to experience a sense of well-being.



Well-Being Yoga - Tuesday Evening - 12/01/2015
Yoga, which increases flexibility, range of motion and strength, may bring additional benefits both during and after cancer treatments. When tension is released, energy flows more easily in the body, allowing participants to experience a sense of well-being.